December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Ocular Transfer of Retinal Muller Cells (RMG) Tramsdiced In Vitro with Adenovirus Expressing Viral IL-10 (Ad-vIL-10) and/or CTLA-4Ig (Ad-CTLA4-Ig) Inhibits Experimental Autoimmune Uveoretinitis (EAU)
Author Affiliations & Notes
  • Y De Kozak
    Institut Biomed des Cordeliers INSERM U450 Paris France
  • M-C Naud
    Institut Biomed des Cordeliers INSERM U450 Paris France
  • A Delanoye
    Ibl Institut Pasteur de Lille Lille France
  • B Thillaye-Goldenberg
    Institut Biomed des Cordeliers INSERM U450 Paris France
  • C Auriault
    Ibl Institut Pasteur de Lille Lille France
  • M Wood
    University of Oxford Oxford United Kingdom
  • C Verwaerde
    Ibl Institut Pasteur de Lille Lille France
  • Footnotes
    Commercial Relationships   Y. De Kozak, None; M. Naud, None; A. Delanoye, None; B. Thillaye-Goldenberg, None; C. Auriault, None; M. Wood, None; C. Verwaerde, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1949. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y De Kozak, M-C Naud, A Delanoye, B Thillaye-Goldenberg, C Auriault, M Wood, C Verwaerde; Ocular Transfer of Retinal Muller Cells (RMG) Tramsdiced In Vitro with Adenovirus Expressing Viral IL-10 (Ad-vIL-10) and/or CTLA-4Ig (Ad-CTLA4-Ig) Inhibits Experimental Autoimmune Uveoretinitis (EAU) . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1949.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: We have previously reported that subconjunctival or retrobulbar injection of Ad-vIL-10 performed in rodents determined a reduction of EAU. Besides, blockade of CD28-B7 interactions by soluble CTLA4-Ig fusion protein has been shown to ameliorate several autoimmune diseases including EAU. Our purpose was to improve the expression of the transgene in the eye and its effect on EAU by injecting into the vitreous either free recombinant Ad-vIL-10 or RMG cells infected in vitro with Ad-vIL-10 (RMG-vIL-10) and/or RMG infected in vitro with Ad-CTLA-4Ig (RMG-CTLA-4Ig). Methods: RMG cells were purified from normal Lewis rat retina. Free Ad-vIL-10 (1x109 pfu in 10ul) or RMG-vIL-10 and/or RMG-CTLA4-Ig (1.5-3x105 cells in 10ul) were injected into the vitreous of Lewis rats. Eyes were taken at 3, 7 and 13 days to evaluate the expression of vIL-10 mRNA by RT-PCR. Intravitreal injection of RMG-vIL-10 was performed the day of S-antigen footpad immunization or 10 days later. Histopathology, Ag-specific ear skin tests, lymphocyte proliferation and cytokine titration were performed 21 days after immunization. Results: Unilateral injection of free Ad-vIL-10 resulted in a reduced EAU (36% inhibition) only in the treated eye demonstrating a local origin of the beneficial effect. High levels of vIL-10 mRNA expression were detected in ocular tissues up to 13 days after RMG-vIL-10 ocular injection whereas no vIL-10 was detectable in the sera. The injection of RMG-Ad-vIL-10 simultaneously with or 10 days after immunization induced an inhibition of EAU (respectively 31% and 22%); the injection of RMG-CTLA4-Ig induced 39% suppression of EAU. Interestingly, co-administration of RMG-vIL-10+RMG-CTLA4-Ig resulted in an enhanced inhibition of the disease (47%). No effect on the systemic immune response was observed in treated rats. Conclusion: The efficiency of local gene delivery of vIL-10+CTLA4-Ig by RMG cells may suggest a valuable therapeutic potential for this gene transfer strategy in uveitis.

Keywords: 612 uveitis-clinical/animal model • 327 autoimmune disease • 435 immunomodulation/immunoregulation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×